Robert D. Schouten

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.3K citations · Full text

Advanced Lung Cancer, Cancer Immunosurveillance, Medicine +12

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma

Josine M.M.F. Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries et al. · Journal of Thoracic Oncology · 2018 · 244 citations · Full text

Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath

R. de Vries, Mirte Muller, Vincent van der Noort et al. · Annals of Oncology · 2019 · 76 citations · Full text

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).

Julien Mazieres, Alexander Drilon, Laurent Mhanna et al. · Journal of Clinical Oncology · 2018 · 54 citations

Immunology, Pathology, Immunotherapy +19

OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies

Josine M.M.F. Quispel-Janssen, Giulia Zago, Robert D. Schouten et al. · Journal of Thoracic Oncology · 2017 · 52 citations · Full text

Malignant Pleural Mesothelioma, Medicine, Pathology +4